☆ 4.2 Article

Role of CD19 Chimeric Antigen Receptor T Cells in Second-Line Large B Cell Lymphoma: Lessons from Phase 3 Trials. An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy

TRANSPLANTATION AND CELLULAR THERAPY (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Hematology

Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission

Mazyar Shadman et al.

Summary: The relative efficacy of autologous hematopoietic cell transplant (auto-HCT) vs chimeric antigen receptor T-cell (CAR-T) therapy in patients with diffuse large B-cell lymphoma (DLBCL) who achieve a partial remission (PR) after salvage chemotherapy is not known. A study found that auto-HCT treatment was associated with a lower rate of relapse and superior overall survival compared to CAR-T treatment in DLBCL patients in PR after salvage therapy. These findings support auto-HCT as the standard of care for transplant-eligible patients with relapsed DLBCL in PR after salvage therapy.

BLOOD (2022)

添加到收藏夹

Article Oncology

The AntiCD19 Antibody Drug Immunoconjugate Loncastuximab Achieves Responses in DLBCL Relapsing After AntiCD19 CAR-T Cell Therapy

Paolo F. Caimi et al.

Summary: The antibody loncastuximab tesirine, which targets CD19 surface antigen, has shown efficacy in patients with disease progression after CAR-T cell therapy. Six out of thirteen patients (46%) had a treatment response with median overall survival, progression-free survival, and duration of response of 8.2, 1.4, and 8 months, respectively. Loncastuximab tesirine may be considered as a treatment option for these patients.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2022)

添加到收藏夹

Article Oncology

Impact of TP53 Genomic Alterations in Large B-Cell Lymphoma Treated With CD19-Chimeric Antigen Receptor T-Cell Therapy

Roni Shouval et al.

Summary: TP53 mutations/CNAs are important determinants of response and survival in LBCL patients treated with CD19-CAR-T therapy. TP53 alterations are associated with poor treatment outcomes and lower survival rates.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

HLA-independent T cell receptors for targeting tumors with low antigen density

Jorge Mansilla-Soto et al.

Summary: HLA-independent T cell receptors (HIT receptors) are a novel type of chimeric antigen receptors that can effectively target tumors with low antigen expression, surpassing the sensitivity of CD28-based receptors. They offer high antigen sensitivity and can recognize tumors beyond the capabilities of other CAR designs. The functional persistence of HIT T cells can be enhanced by coexpression of CD80 and 4-1BBL. HIT receptors have been validated in xenograft mouse models, targeting CD19 and CD70 in B cell leukemia and acute myeloid leukemia, respectively.

NATURE MEDICINE (2022)

添加到收藏夹

Article Medicine, General & Internal

Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma

M. R. Bishop et al.

Summary: Tisagenlecleucel did not demonstrate superiority over standard salvage therapy in this trial. Further studies are needed to evaluate which patients may benefit the most from each approach.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Article Medicine, General & Internal

Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma

F. L. Locke et al.

Summary: This international phase 3 trial showed that axicabtagene ciloleucel therapy significantly improved event-free survival and response in patients with early relapsed or refractory large B-cell lymphoma compared to standard care, despite the expected high-grade toxic effects.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Article Medicine, General & Internal

Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma

Herve Tilly et al.

Summary: In untreated intermediate-risk or high-risk DLBCL patients, those who received pola-R-CHP had a lower risk of disease progression, relapse, or death compared to those who received R-CHOP. Overall survival and safety profiles were similar between the two groups.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Review Immunology

iPSC-Derived Natural Killer Cell Therapies-Expansion and Targeting

Benjamin H. Goldenson et al.

Summary: The use of iPSC-derived NK cells in cancer treatment, particularly hematologic malignancies, has rapidly advanced. Genetic modifications have been employed to enhance tumor targeting, expansion, and persistence of NK cells. This review highlights recent important developments in iPSC-derived NK cell therapies, with a focus on improved cancer targeting. The potential combination of these advances may lead to effective NK cell-based therapies for both hematologic malignancies and solid tumors in the future.

FRONTIERS IN IMMUNOLOGY (2022)

添加到收藏夹

Article Hematology

Allogeneic transplant and CAR-T therapy after autologous transplant failure in DLBCL: a noncomparative cohort analysis

Mehdi Hamadani et al.

Summary: This registry analysis reveals that both CAR-T and alloHCT can result in durable remissions in patients with DLBCL relapsing after an autoHCT. The CIBMTR prognostic model can be used to identify high-risk patients for treatment failure and guide treatment decisions. Evaluation of novel strategies for relapse mitigation after cellular immunotherapies in high-risk patients is needed.

BLOOD ADVANCES (2022)

添加到收藏夹

Article Hematology

Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy

Vanessa A. Fabrizio et al.

Summary: In CAR T-cell therapy, optimizing fludarabine exposure may improve outcomes. Insufficient fludarabine exposure is associated with a higher risk of relapse, suggesting that personalized dosing strategies may reduce disease relapse after CAR T-cell therapy.

BLOOD ADVANCES (2022)

添加到收藏夹

Review Oncology

Allogeneic Chimeric Antigen Receptor Therapy in Lymphoma

Arushi Khurana et al.

Summary: Allogeneic CAR-T therapies have advantages over autologous CAR-T therapies, such as easier accessibility and more stable quality, but they also have complications and require genomic editing. Further research and clinical trials are needed.

CURRENT TREATMENT OPTIONS IN ONCOLOGY (2022)

添加到收藏夹

Article Hematology

Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma

Mahmoud Elsawy et al.

BLOOD (2022)

添加到收藏夹

Article Medicine, General & Internal

Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial

Manali Kamdar et al.

LANCET (2022)

添加到收藏夹

Article Hematology

ASTCT Committee on Practice Guidelines Survey on Evaluation & Management of Diffuse Large B-cell Lymphoma after Failure of Chimeric Antigen Receptor T Cell Therapy (CAR-T) Therapy

Nausheen Ahmed et al.

Summary: Chimeric antigen receptor T-cell therapy (CAR-T) is a significant advancement in managing aggressive relapsed or refractory B-cell lymphomas, but frequent relapses remain a major challenge. There is substantial variability in assessing and managing post-CAR-T failures across transplantation and cellular therapy programs. A survey was conducted among lymphoma, transplantation, and cellular therapy physicians in the United States to determine their practice patterns for the detection, diagnosis, and management of CAR-T failure in diffuse large B-cell lymphoma. The survey revealed significant differences in surveillance, diagnosis, and treatment approaches for CAR-T failure.

TRANSPLANTATION AND CELLULAR THERAPY (2022)

添加到收藏夹

Article Hematology

Therapy Socioeconomic and Racial Disparity in Chimeric Antigen Receptor T Cell Therapy Access

Nausheen Ahmed et al.

Summary: CAR T cell therapy has shown disparities in racial/ethnic distribution, socioeconomic strata, and insurance coverage, with African Americans and Hispanics being underrepresented. Patients living farther from treatment centers tend to be from higher socioeconomic backgrounds. Low enrollment of minorities in clinical trials contributes to these disparities, indicating a need for strategies to address the root causes.

TRANSPLANTATION AND CELLULAR THERAPY (2022)

添加到收藏夹

Review Immunology

Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy

Emma C. Morris et al.

Summary: CAR T cell therapy has revolutionized the field of cancer treatment, but significant toxicities can occur in up to one-third of patients. The most common toxicities include cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome. Understanding their pathophysiology is crucial for developing novel therapeutics for prevention and management.

NATURE REVIEWS IMMUNOLOGY (2022)

添加到收藏夹

Letter Hematology

Impact and safety of chimeric antigen receptor T-cell therapy in older, vulnerable patients with relapsed/refractory large B-cell lymphoma

Richard J. Lin et al.

HAEMATOLOGICA (2021)

添加到收藏夹

Article Hematology

Comorbidities Predict Inferior Survival in Patients Receiving Chimeric Antigen Receptor T Cell Therapy for Diffuse Large B Cell Lymphoma: A Multicenter Analysis

Adam S. Kittai et al.

Summary: The study on 130 patients receiving CAR-T therapy for R/R DLBCL found that high CIRS and ECOG PS were associated with inferior overall survival. Multivariable analysis showed that comorbidities based on CIRS and ECOG PS can predict the survival prognosis of these patients.

TRANSPLANTATION AND CELLULAR THERAPY (2021)

添加到收藏夹

Article Hematology

Outcomes of Autologous Hematopoietic Cell Transplantation in Diffuse Large B Cell Lymphoma Refractory to Firstline Chemoimmunotherapy

Susan Bal et al.

Summary: In the modern era, the role of autologous hematopoietic cell transplant (autoHCT) in patients with primary refractory DLBCL who show chemosensitive disease after salvage therapies provides durable disease control. Patients achieving complete remission (CR) with salvage therapy had better progression-free survival (PFS) outcomes compared to those in partial remission (PR), highlighting the importance of autoHCT in this population.

TRANSPLANTATION AND CELLULAR THERAPY (2021)

添加到收藏夹

Article Hematology

Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies

Jordan Gauthier et al.

Summary: CD19 CAR T-cell therapy has shown significant efficacy for R/R B-cell malignancies, but durable responses are limited. Second infusions of CD19 CAR T cells (CART2) can improve outcomes, with positive therapeutic effects observed in CLL, NHL, and ALL patients after CART2.

BLOOD (2021)

添加到收藏夹

Article Hematology

CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR-refractory large B-cell lymphoma

John H. Baird et al.

Summary: Despite poor prognosis in LBCL patients following CAR19 therapy failure, treatment with CAR22 in three consecutive patients showed promising results with all patients achieving complete remission and experiencing tolerable side effects, suggesting potential efficacy of CAR22 therapy in this population.

BLOOD (2021)

添加到收藏夹

Review Oncology

How to Sequence Therapies in Diffuse Large B-Cell Lymphoma Post-CAR-T Cell Failure

Jennifer M. Logue et al.

Summary: Post CAR-T failures in R/R LBCL present a new unmet need with very poor prognosis. Standard treatment options are lacking, although FDA-approved medications like polatuzumab, tafasitamab, selinexor, and loncastuximab tesirine are available, data in this setting is limited. Clinical trials with bi-specific antibodies show encouraging results with manageable toxicities, suggesting their potential in this scenario. Additional cell therapies like dual CAR-T or allogeneic products may also be considered, but challenges with logistics and further immunosuppression need to be addressed. Consolidation with stem cell transplantation could be an option for eligible patients.

CURRENT TREATMENT OPTIONS IN ONCOLOGY (2021)

添加到收藏夹

Article Hematology

Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma

John H. Baird et al.

Summary: CAR T-cell therapy targeting CD19 improves outcomes in LBCL treatment, but long-term monitoring of hematologic recovery, immune reconstitution, and antimicrobial prophylaxis is necessary for patients post-treatment.

BLOOD ADVANCES (2021)

添加到收藏夹

Article Hematology

Is autologous transplant in relapsed DLBCL patients achieving only a PET+ PR appropriate in the CAR T-cell era?

Nirav N. Shah et al.

Summary: For relapsed chemosensitive DLBCL patients with residual PET/CT+ disease prior to auto-HCT, the adjusted 5-year PFS was comparable, irrespective of time to relapse. These data support ongoing application of auto-HCT in chemosensitive DLBCL.

BLOOD (2021)

添加到收藏夹

Letter Medicine, General & Internal

Five-Year Outcomes for Refractory B-Cell Lymphomas with CAR T-Cell Therapy

Elise A. Chong et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Hematology

The evolving role of allogeneic haematopoietic cell transplantation in the era of chimaeric antigen receptor T-cell therapy

Bhagirathbhai Dholaria et al.

Summary: CAR T therapy has shown impressive disease responses in B-NHL and B-ALL patients, but there are differences in outcomes and treatment strategies based on age groups. Allogeneic HCT may improve survival in high-risk B-ALL patients after CD19 CAR T therapy.

BRITISH JOURNAL OF HAEMATOLOGY (2021)

添加到收藏夹

Review Oncology

Diffuse large B-cell lymphoma: new targets and novel therapies

Bruce D. Cheson et al.

Summary: Newer, more effective and non-cytotoxic therapies are needed for patients with DLBCL and other B-cell malignancies. Approved treatments include various combinations of drugs, CAR-T cell products, and ongoing development of other therapies. Combinations of targeted therapies are expected to further improve the outcomes for patients.

BLOOD CANCER JOURNAL (2021)

添加到收藏夹

Article Hematology

CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma

Kai Rejeski et al.

Summary: Hematotoxicity is a common adverse event in CAR T-cell therapy, with baseline thrombocytopenia and hyperferritinemia being significant predictive markers. The CAR-HEMATOTOX model can accurately predict the occurrence of severe neutropenia.

BLOOD (2021)

添加到收藏夹

Review Immunology

CAR T cells: Building on the CD19 paradigm

Anat Globerson-Levin et al.

Summary: Therapeutic use of CARs targeting CD19 has led to significant success in treating B-cell malignancies, sparking interest in T-cell engineering and cancer immunotherapy. Advances in CAR design, cell manufacturing, and genome editing hold promise for safer and more effective genetically instructed immunity, with potential applications in a wide range of diseases in the future.

EUROPEAN JOURNAL OF IMMUNOLOGY (2021)

添加到收藏夹

Article Oncology

Allogeneic stem cell transplant in non-Hodgkin lymphomas: Still an indication?

Peter Dreger

Summary: With the development of modern targeted molecular therapies and immunotherapies, the traditional role of allogeneic hematopoietic cell transplantation in the treatment of non-Hodgkin lymphoma is being questioned.

HEMATOLOGICAL ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study

Stephen J. Schuster et al.

Summary: The JULIET trial evaluated the long-term treatment outcomes and safety of tisagenlecleucel in adult patients, showing durable activity and manageable safety profiles in patients with relapsed or refractory aggressive B-cell lymphomas. Tisagenlecleucel compared favorably with conventional therapeutic approaches for patients with large B-cell lymphomas that are refractory to chemoimmunotherapy or relapsing after second-line therapies.

LANCET ONCOLOGY (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial

Jay Y. Spiegel et al.

Summary: Despite impressive progress in CAR-T cell therapy, more than 50% of patients treated with CD19-targeting CAR-T cells experience disease progression, often associated with antigen loss. To address this issue, researchers tested a bispecific CAR targeting CD19 and/or CD22, which showed high efficacy in preventing relapse in patients with B-ALL and LBCL. Antigen loss was identified as a major cause of CAR T cell resistance, emphasizing the importance of engineering multi-specific CAR T cells with equivalent potency and cytokine production as a quality indicator for potency.

NATURE MEDICINE (2021)

添加到收藏夹

Review Virology

Lentiviral Vectors for T Cell Engineering: Clinical Applications, Bioprocessing and Future Perspectives

Roman P. Labbe et al.

Summary: Lentiviral vectors are crucial in the development of T cell therapies such as tisagenlecleucel, axicabtagene ciloleucel, and brexucabtagene autoleucel. However, obstacles remain in making these therapies widely available. The development of GMP-compliant technologies will play a key role in advancing lentiviral vector-engineered T cell therapies.

VIRUSES-BASEL (2021)

添加到收藏夹

Review Oncology

Balancing Quality, Cost, and Access During Delivery of Newer Cellular and Immunotherapy Treatments

Praveen Ramakrishnan Geethakumari et al.

Summary: CAR T-cell therapy is revolutionizing the treatment of hematologic malignancies, but its administration process is complex, labor-intensive, and expensive, requiring further optimization. Cellular immunotherapy is poised to impact the future of solid tumors and non-oncological diseases, yet challenges in treatment administration and quality management remain critical for widespread implementation and access improvement.

CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2021)

添加到收藏夹

Letter Hematology

Blueprint for the discovery of biomarkers of toxicity and efficacy for CAR T cells and T-cell engagers

Sophie Paczesny et al.

BLOOD ADVANCES (2021)

添加到收藏夹

Article Hematology

Toxicities of high-dose chemotherapy and autologous hematopoietic cell transplantation in older patients with lymphoma

Parastoo B. Dahi et al.

Summary: High-dose chemotherapy followed by autologous hematopoietic cell transplantation (AHCT) in lymphoma patients has been found to be effective, but older patients, especially those aged 70 and above, are at a higher risk of developing severe toxicities, including cardiovascular and skin toxicities. Nonrelapse mortality rates were higher in older patients compared to younger ones, and older patients had an increased risk of progression or death within the first 100 days post-treatment. Further interventions are needed to minimize toxicities while maintaining treatment efficacy.

BLOOD ADVANCES (2021)

添加到收藏夹

Article Hematology

Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells

Martina Pennisi et al.

Summary: This study found that EASIX and two modified EASIX formulas can predict severe toxicities related to CAR T-cell therapy, with CRP and PLTs being the most significant variables associated with these toxicities. m-EASIX was identified as a critical predictor of disease response and had high discriminatory ability for diagnosing patients with severe CRS and ICANS.

BLOOD ADVANCES (2021)

添加到收藏夹

Review Hematology

State of the CAR-T: Risk of Infections with Chimeric Antigen Receptor T-Cell Therapy and Determinants of SARS-CoV-2 Vaccine Responses

Juliet Meir et al.

Summary: CAR-T therapy has shown unprecedented response rates in patients with relapsed/refractory hematologic malignancies, but poses distinctive short- and long-term toxicities and infection risks.

TRANSPLANTATION AND CELLULAR THERAPY (2021)

添加到收藏夹

Review Hematology

Chimeric Antigen Receptor T Cell Therapy: A Comprehensive Review of Clinical Efficacy, Toxicity, and Best Practices for Outpatient Administration

Maurice Alexander et al.

Summary: CAR T therapy has become an integral part of treatment for acute leukemia, lymphoma, and multiple myeloma, with a growing number of clinical trials in both hematologic and solid tumor malignancies. Clinical toxicities include cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome. Despite the expected shift towards outpatient administration and monitoring, reimbursement for inpatient treatment poses a threat to the sustainability of inpatient CAR T therapy.

TRANSPLANTATION AND CELLULAR THERAPY (2021)

添加到收藏夹

Article Hematology

Cost Effectiveness Analysis of Tisagenlecleucel for the Treatment of Adult Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma in Japan

Shiho Wakase et al.

Summary: The study evaluated the cost-effectiveness of tisagenlecleucel treatment strategy versus salvage chemotherapy for adult patients with r/r DLBCL in Japan. The results showed that tisagenlecleucel was more effective in prolonging survival and improving quality of life compared to salvage chemotherapy, making it a cost-effective treatment option from a Japanese public healthcare payer's perspective.

TRANSPLANTATION AND CELLULAR THERAPY (2021)

添加到收藏夹

Review Hematology

Late Effects after Chimeric Antigen Receptor T Cell Therapy for Lymphoid Malignancies

Rajshekhar Chakraborty et al.

Summary: CAR T cell therapy has revolutionized the treatment of relapsed/refractory lymphoid malignancies, with late toxicities including hypogammaglobulinemia, prolonged cytopenias, late infections, neurologic and neuropsychiatric effects, immune-related late effects, and subsequent malignancies. Factors contributing to late toxicities include age, tumor type, previous therapy, CAR construct, and acute toxicities. Further research is needed to understand the long-term effects of CAR T cell therapy.

TRANSPLANTATION AND CELLULAR THERAPY (2021)

添加到收藏夹

Article Hematology

The International Prognostic Index Is Associated with Outcomes in Diffuse Large B Cell Lymphoma after Chimeric Antigen Receptor T Cell Therapy

Marta Garcia-Recio et al.

Summary: High-risk IPI or aaIPI are associated with inferior PFS in R/R DLBCL patients undergoing CAR T cell therapy, while aaIPI and IPI are linked to OS and neurotoxicity, respectively. CCI is not correlated with toxicities or outcomes, and associations with HCT-CI remain inconclusive due to small sample size. Indices like IPI and aaIPI can help guide patient selection for CD19 CAR T cell therapy.

TRANSPLANTATION AND CELLULAR THERAPY (2021)

添加到收藏夹

Article Hematology

Late Events after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T Cells

Ana Cordeiro et al.

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2020)

添加到收藏夹

Article

Resource Utilization and Factors Prolonging Hospitalization for Patients with Refractory and Relapsed B-Cell Lymphoma Receiving Axicabtagene Ciloleucel (Axi-cel)

Agrima Mian et al.

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2020)

添加到收藏夹

Article Hematology

Early experience using salvage radiotherapy for relapsed/refractory non-Hodgkin lymphomas after CD19 chimeric antigen receptor (CAR) T cell therapy

[Anonymous]

BRITISH JOURNAL OF HAEMATOLOGY (2020)

添加到收藏夹

Article Oncology

Outcomes of Rituximab-BEAM Versus BEAM Conditioning Regimen in Patients With Diffuse Large B Cell Lymphoma Undergoing Autologous Transplantation

Deepa Jagadeesh et al.

CANCER (2020)

添加到收藏夹

Article Hematology

Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma

Sattva S. Neelapu et al.

BLOOD (2020)

添加到收藏夹

Review Biophysics

CAR T-cell therapy for the management of refractory/relapsed high-grade B-cell lymphoma: a practical overview

Mohamad Mohty et al.

BONE MARROW TRANSPLANTATION (2020)

添加到收藏夹

Article Oncology

Retreatment (reTx) of patients (pts) with refractory large B-cell lymphoma with axicabtagene ciloleucel (axi-cel) in ZUMA-1.

Frederick Lundry Locke et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Hematology

DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality

Kitsada Wudhikarn et al.

BLOOD ADVANCES (2020)

添加到收藏夹

Article Hematology

Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies

Tania Jain et al.

BLOOD ADVANCES (2020)

添加到收藏夹

Article Oncology

Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study

Gilles Salles et al.

LANCET ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma

Kitsada Wudhikarn et al.

BLOOD CANCER JOURNAL (2020)

添加到收藏夹

Article Medicine, General & Internal

Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study

Jeremy S. Abramson et al.

LANCET (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial

Nirav N. Shah et al.

NATURE MEDICINE (2020)

添加到收藏夹

Article Hematology

CAR T cells or allogeneic transplantation as standard of care for advanced large B-cell lymphoma: an intent-to-treat comparison

Peter Dreger et al.

BLOOD ADVANCES (2020)

添加到收藏夹

Meeting Abstract Hematology

Odronextamab (REGN1979), a Human CD20 x CD3 Bispecific Antibody, Induces Durable, Complete Responses in Patients with Highly Refractory B-Cell Non-Hodgkin Lymphoma, Including Patients Refractory to CAR T Therapy

Rajat Bannerji et al.

BLOOD (2020)

添加到收藏夹

Meeting Abstract Hematology

Subcutaneous Epcoritamab Induces Complete Responses with an Encouraging Safety Profile across Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Subtypes, Including Patients with Prior CAR-T Therapy: Updated Dose Escalation Data

Martin Hutchings et al.

BLOOD (2020)

添加到收藏夹

Article Medicine, General & Internal

Economic Evaluation of Chimeric Antigen Receptor T-Cell Therapy by Site of Care Among Patients With Relapsed or Refractory Large B-Cell Lymphoma

Gary H. Lyman et al.

JAMA NETWORK OPEN (2020)

添加到收藏夹

Article Hematology

Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management

Martina Pennisi et al.

BLOOD ADVANCES (2020)

添加到收藏夹

Article

Thirty Day Resource Utilization after Chimeric Antigen Receptor (CAR) T Cell Infusion for Hematologic Malignancies

Gunjan L. Shah et al.

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)

添加到收藏夹

Letter Hematology

Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy

Victor A. Chow et al.

AMERICAN JOURNAL OF HEMATOLOGY (2019)

添加到收藏夹

Article

Understanding and Managing Large B Cell Lymphoma Relapses after Chimeric Antigen Receptor T Cell Therapy

Michael Byrne et al.

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)

添加到收藏夹

Article Oncology

Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Multiply Relapsed or Refractory Adult Large B-Cell Lymphoma

John K. Lin et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

添加到收藏夹

Article Hematology

Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy

Tania Jain et al.

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)

添加到收藏夹

Letter Hematology

CAR T cell viability release testing and clinical outcomes: is there a lower limit?

Elise A. Chong et al.

BLOOD (2019)

添加到收藏夹

Article Hematology

Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL

Kevin J. Curran et al.

BLOOD (2019)

添加到收藏夹

Review Oncology

CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives

Mohamad Mohty et al.

LEUKEMIA (2019)

添加到收藏夹

Article Hematology

ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells

Daniel W. Lee et al.

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)

添加到收藏夹

Article Oncology

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial

Frederick L. Locke et al.

LANCET ONCOLOGY (2019)

添加到收藏夹

Article Medicine, General & Internal

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Stephen J. Schuster et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

添加到收藏夹

Article Hematology

Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapy

Mazyar Shadman et al.

BLOOD ADVANCES (2019)

添加到收藏夹

Review Hematology

The Role of Autologous Stem Cell Transplantation in the Treatment of Diffuse Large B-cell Lymphoma in the Era of CAR-T Cell Therapy

Lazaros J. Lekakis et al.

HEMASPHERE (2019)

添加到收藏夹

Review Hematology

CAR T Cell Toxicity: Current Management and Future Directions

Lucrecia Yanez et al.

HEMASPHERE (2019)

添加到收藏夹

Review Hematology

Building a CAR Garage: Preparing for the Delivery of Commercial CAR T Cell Products at Memorial Sloan Kettering Cancer Center

Karlo Perica et al.

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2018)

添加到收藏夹

Article Oncology

Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia

Bianca D. Santomasso et al.

CANCER DISCOVERY (2018)

添加到收藏夹

Letter Oncology

Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy

Inmaculada Hernandez et al.

JAMA ONCOLOGY (2018)

添加到收藏夹

Article Oncology

Treatment outcomes for older patients with relapsed/refractory aggressive lymphoma receiving salvage chemotherapy and autologous stem cell transplantation are similar to younger patients: a subgroup analysis from the phase III CCTG LY.12 trial

K. Davison et al.

ANNALS OF ONCOLOGY (2017)

添加到收藏夹

Article Oncology

Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation

Alex F. Herrera et al.

JOURNAL OF CLINICAL ONCOLOGY (2017)

添加到收藏夹

Article Medicine, General & Internal

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

S. S. Neelapu et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

添加到收藏夹

Editorial Material Oncology

The Why, what, and How of the New FACT standards for immune effector cells

Marcela V. Maus et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)

添加到收藏夹

Article Hematology

Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study

Michael Crump et al.

BLOOD (2017)

添加到收藏夹

Article Hematology

Diffuse large B-cell lymphoma with primary treatment failure: Ultra-high risk features and benchmarking for experimental therapies

Luciano J. Costa et al.

AMERICAN JOURNAL OF HEMATOLOGY (2017)

添加到收藏夹

Article Biophysics

Geographic access to hematopoietic cell transplantation services in the United States

P. L. Delamater et al.

BONE MARROW TRANSPLANTATION (2016)

添加到收藏夹

Article Hematology

Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation

Timothy S. Fenske et al.

BRITISH JOURNAL OF HAEMATOLOGY (2016)

添加到收藏夹

Article Hematology

Does microbial contamination influence the success of the hematopoietic cell transplantation outcomes?

Mehmet Sinan Dal et al.

TRANSFUSION AND APHERESIS SCIENCE (2016)

添加到收藏夹

Article Hematology

Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma

Craig S. Sauter et al.

BLOOD (2015)

添加到收藏夹

Article Hematology

Early Failure of Frontline Rituximab-Containing Chemo-immunotherapy in Diffuse Large B Cell Lymphoma Does Not Predict Futility of Autologous Hematopoietic Cell Transplantation

Mehdi Hamadani et al.

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2014)

添加到收藏夹

Review Hematology

Current concepts in the diagnosis and management of cytokine release syndrome

Daniel W. Lee et al.

BLOOD (2014)

添加到收藏夹

Article Oncology

Randomized Comparison of Gemcitabine, Dexamethasone, and Cisplatin Versus Dexamethasone, Cytarabine, and Cisplatin Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: NCIC-CTG LY.12

Michael Crump et al.

JOURNAL OF CLINICAL ONCOLOGY (2014)

添加到收藏夹

Article Oncology

Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification

Bruce D. Cheson et al.

JOURNAL OF CLINICAL ONCOLOGY (2014)

添加到收藏夹

Editorial Material Medicine, General & Internal

Updating Cost-Effectiveness - The Curious Resilience of the $50,000-per-QALY Threshold

Peter J. Neumann et al.

NEW ENGLAND JOURNAL OF MEDICINE (2014)

添加到收藏夹

Article Hematology

Prognostic factors for patients with diffuse large B cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation in the positron emission tomography era

Philippe Armand et al.

BRITISH JOURNAL OF HAEMATOLOGY (2013)

添加到收藏夹

Article Oncology

Phase III Randomized Study of Rituximab/Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) Compared With Iodine-131 Tositumomab/BEAM With Autologous Hematopoietic Cell Transplantation for Relapsed Diffuse Large B-Cell Lymphoma: Results From the BMT CTN 0401 Trial

Julie M. Vose et al.

JOURNAL OF CLINICAL ONCOLOGY (2013)

添加到收藏夹

Article Hematology

Microbial contamination of hematopoietic progenitor and other regenerative cells used in transplantation and regenerative medicine

Michael R. Jacobs et al.

TRANSFUSION (2013)

添加到收藏夹

Article Hematology

MYC+ diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation

Wendy Cuccuini et al.

BLOOD (2012)

添加到收藏夹

Article Infectious Diseases

Autologous transplant: microbial contamination of hematopoietic stem cell products

Igor Dullius Almeida et al.

BRAZILIAN JOURNAL OF INFECTIOUS DISEASES (2012)

添加到收藏夹

Article Oncology

Rituximab Maintenance Therapy After Autologous Stem-Cell Transplantation in Patients With Relapsed CD20+ Diffuse Large B-Cell Lymphoma: Final Analysis of the Collaborative Trial in Relapsed Aggressive Lymphoma

Christian Gisselbrecht et al.

JOURNAL OF CLINICAL ONCOLOGY (2012)

添加到收藏夹

Article Medicine, General & Internal

Peripheral-Blood Stem Cells versus Bone Marrow from Unrelated Donors

Claudio Anasetti et al.

NEW ENGLAND JOURNAL OF MEDICINE (2012)

添加到收藏夹

Article Oncology

Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era

Christian Gisselbrecht et al.

JOURNAL OF CLINICAL ONCOLOGY (2010)

添加到收藏夹

Article Hematology

Peripheral blood grafts from unrelated donors are associated with increased acute and chronic graft-versus-host disease without improved survival

Mary Eapen et al.

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2007)

添加到收藏夹

Article Medicine, General & Internal

The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma

A Rosenwald et al.

NEW ENGLAND JOURNAL OF MEDICINE (2002)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.